Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.94 HKD | -2.94% | +0.85% | -11.08% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
Business Summary
Number of employees: 444
Sales per Business
HKD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Ophthalmic Pharmaceutical Platform
100.0
%
| 68 | 100.0 % | 185 | 100.0 % | +173.17% |
Sales per region
HKD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
China
100.0
%
| 68 | 100.0 % | 185 | 100.0 % | +173.17% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ye Liu
CEO | Chief Executive Officer | 53 | 18-07-31 |
Tim Ruan
DFI | Director of Finance/CFO | 38 | 23-01-11 |
Dong Hong Chen
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-10-27 |
Zhao Peng Hu
BRD | Director/Board Member | 51 | 18-09-02 |
Ting Chan Chen
SEC | Corporate Secretary | 30 | 21-06-30 |
Qinglei Zuo
PRN | Corporate Officer/Principal | 40 | 20-12-31 |
Hong Ying Liu
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Li
BRD | Director/Board Member | 52 | 18-03-31 |
Yan Ling Cao
BRD | Director/Board Member | 39 | 19-06-17 |
Ting Yuk Wu
BRD | Director/Board Member | 69 | 20-06-22 |
Lian Yong Chen
CHM | Chairman | 62 | 18-05-22 |
Yumeng Wang
BRD | Director/Board Member | 33 | 21-03-18 |
Zhenyu Zhang
BRD | Director/Board Member | 50 | 22-04-07 |
Ye Liu
CEO | Chief Executive Officer | 53 | 18-07-31 |
Zhao Peng Hu
BRD | Director/Board Member | 51 | 18-09-02 |
Yi Ran Huang
BRD | Director/Board Member | 69 | 20-06-22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 695,614,850 | 330,899,975 ( 47.57 %) | 0 | 47.57 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
ALIMERA SCIENCES, INC. 2.19% | 1,144,945 | 2.19% | 4,465,286 $ |
100,221 | 0.20% | 2,071,568 $ |
Company contact information
Ocumension Therapeutics
No. 1858 Yinzhongnan Road Guoxiang Subdistrict
215000, Suzhou
+
http://www.ocumension.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.08% | 542M | |
+27.51% | 672B | |
+24.27% | 550B | |
-6.87% | 351B | |
+15.09% | 317B | |
+6.42% | 292B | |
+2.81% | 211B | |
-0.05% | 203B | |
-11.41% | 144B | |
-8.48% | 141B |
- Stock Market
- Equities
- 1477 Stock
- Company Ocumension Therapeutics